Indivior Shares Surge After Strong Quarterly Results and Higher 2026 Outlook

Indivior Pharmaceuticals Inc. (NASDAQ:INDV) reported better-than-expected second-quarter 2026 results on Monday, driven by record sales of its opioid use disorder treatment SUBLOCADE, while raising its full-year financial guidance.

The stronger outlook sent the pharmaceutical company’s shares up 9.22% in pre-market trading.

Earnings and Revenue Top Expectations

Indivior posted adjusted earnings of $1.15 per share for the second quarter, comfortably exceeding analysts’ consensus estimate of $0.74.

Quarterly revenue reached $343 million, ahead of the market forecast of $284.9 million and up 14% from $302 million in the same period last year.

Record SUBLOCADE Sales Fuel Growth

The company’s performance was underpinned by record quarterly net revenue from SUBLOCADE, which climbed 21% year over year to $253 million.

Growth was supported by an 18% increase in dispense unit volumes, together with favorable pricing and product mix.

In the United States, SUBLOCADE generated net revenue of $238 million, while new patient starts reached a record 32,816 during the quarter.

Company Raises Full-Year Guidance

Following the strong first-half performance, Indivior increased its financial outlook for fiscal 2026.

The company now expects full-year revenue to range between $1.295 billion and $1.365 billion. The midpoint of $1.33 billion is well above analysts’ consensus estimate of $1.26 billion.

Net revenue guidance for SUBLOCADE was also raised to between $1.01 billion and $1.05 billion, compared with the previous forecast of $950 million to $990 million.

In addition, adjusted EBITDA guidance was lifted to a range of $700 million to $740 million from the prior outlook of $620 million to $660 million.

Management Highlights Operational Execution

Chief Executive Officer Joe Ciaffoni credited the company’s commercial execution for the improved results and outlook.

“Exceptional operational execution in Phase II – Accelerate – of the Indivior Action Agenda fueled strong SUBLOCADE performance in the quarter and is the primary driver of our raised 2026 guidance,” said Joe Ciaffoni, Chief Executive Officer.

Profitability and Capital Returns Improve

Adjusted EBITDA reached a record $186 million during the second quarter, more than doubling from $88 million in the prior-year period, representing year-over-year growth of 111%.

Indivior also continued returning capital to shareholders by repurchasing approximately 4.7 million shares during the quarter for $175 million, at an average purchase price of $37.52 per share.

The company ended the quarter with cash and investments totaling $249 million.

Indivior stock price